Azitra Enters SPA With New And Existing Investors, Secures Up To $31.4M In Convertible Preferred Stock And Warrants To Launch Innovative Protein And Peptide Research For Cosmetic And Cosmeceutical Markets

Azitra, Inc. has entered into a securities purchase agreement with new and existing investors, securing up to $31.4 million in funding through convertible preferred stock and warrants. The initial funding amounts to approximately $10.5 million, with the potential for an additional $20.9 million upon the exercise of warrants. This financing will support the launch of innovative protein and peptide research for the cosmetic and cosmeceutical markets, leveraging Azitra's genetic engineering platform. The transaction is expected to close around March 20, 2026.